Patents by Inventor Gary ARBIQUE

Gary ARBIQUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220370248
    Abstract: The present disclosure provides a removable eyewear shielding device, an eyewear comprising a removable eyewear shielding device, and methods of uses thereof for reducing eye radiation exposure, reducing ipsilateral brain radiation exposure, reducing FGI-induced lens opacification, reducing cataract development, or protecting an eye or ipsilateral brain from radiation exposure.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 24, 2022
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Melissa KIRKWOOD, Jeffrey GUILD, Gary ARBIQUE
  • Patent number: 10363008
    Abstract: Computed tomography perfusion (CTP) is used in a method to identify cancerous lesions having genetic mutations and treat them accordingly. Also, CTP values are used to distinguish primary versus metastatic lesions. For example, pulmonary blood flow is identified as one biomarker for EGFR and KRAS genetic mutations in lung cancer, lesion having dual-input pulmonary blood flow exceeding a threshold (e.g., 103 ml/min/100 mL with sensitivity 100% and specificity 62%) are determined as having mutations. The CTP values are calculated using a lesion region-of-interest (ROI) placed to include the area of maximum perfusion intensity within the lesion base and surrounding blush, while avoiding regions of perfusion inhomogeneity (e.g., due to necrosis). In certain implementations, instead of a binary determination, the method can generate probabilities associated with respective alternatives (e.g.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 30, 2019
    Assignees: Canon Medical Systems USA, Inc., Board of Regents of the University of Texas System
    Inventors: Eugene A. Mensah, Cecelia Brewington, Erin Angel, Gary Arbique, Shaun Nordeck
  • Publication number: 20190159744
    Abstract: Computed tomography perfusion (CTP) is used in a method to identify cancerous lesions having genetic mutations and treat them accordingly. Also, CTP values are used to distinguish primary versus metastatic lesions. For example, pulmonary blood flow is identified as one biomarker for EGFR and KRAS genetic mutations in lung cancer, lesion having dual-input pulmonary blood flow exceeding a threshold (e.g., 103 ml/min/100 mL with sensitivity 100% and specificity 62%) are determined as having mutations. The CTP values are calculated using a lesion region-of-interest (ROI) placed to include the area of maximum perfusion intensity within the lesion bass and surrounding blush, while avoiding regions of perfusion inhomogeneity (e.g., due to necrosis). In certain implementations, instead of a binary determination, the method can generate probabilities associated with respective alternatives (e.g.
    Type: Application
    Filed: November 27, 2017
    Publication date: May 30, 2019
    Applicants: Toshiba America Medical Systems, Inc., Board of Regents of the University of Texas System
    Inventors: Eugene A. MENSAH, Cecelia BREWINGTON, Erin ANGEL, Gary ARBIQUE, Shaun NORDECK